Table 4 Determinants of time to achieve HAQ-DI ≤ 0.5 mm and achievement at week 100 among guselkumab-randomized patients (N = 493)

Age, years

0.98 (0.97–0.99)^†

0.98 (0.97–0.99)^†

0.98 (0.96–1.00)^*

0.98 (0.96–1.00)^*

Sex (male vs. female)

1.17 (0.90–1.52)

-

1.38 (0.90–2.13)

-

Race (White vs. Asian)

2.36 (0.58–9.66)

-

2.52 (0.50–12.69)

-

BMI, kg/m²

0.99 (0.97–1.02)

-

0.98 (0.95–1.02)

-

Guselkumab treatment (Q4W vs., Q8W)

1.01 (0.79–1.30)

-

0.98 (0.64–1.51)

-

HAQ-DI score (0-3)

0.32 (0.23–0.45)^‡

0.26 (0.19–0.36)^‡

0.16 (0.10–0.27)^‡

0.13 (0.08–0.20)^‡

PtGA VAS (0–10 cm)

-

-

-

-

Pt Pain VAS (0–10 cm)

-

-

-

-

FACIT-Fatigue^§

1.01 (1.00–1.03)

-

1.02 (0.99–1.05)

-

History of depression

1.55 (0.64–3.77)

-

1.98 (0.35–11.30)

-

Suicidal ideation or non-suicidal self-injurious behaviour (N = 9)

0.20 (0.03–1.42)

-

0.15 (0.03–0.88)^*

0.16 (0.03–0.86)^*

History of fibromyalgia (N = 3)

0.87 (0.68–1.13)

-

0.84 (0.54–1.30)

-